Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma

Published:2024-07-01 Issue:7 Volume:10 Page:979
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Saifi Omran¹,Breen William G.²,Rule William G.³,Lin Yi⁴⁵,Munoz Javier⁶,Kharfan-Dabaja Mohamed A.⁷,Peterson Jennifer L.¹

Affiliation:

1. Department of Radiation Oncology, Mayo Clinic Jacksonville, Jacksonville, Florida

2. Department of Radiation Oncology, Mayo Clinic Rochester, Rochester, Minnesota

3. Department of Radiation Oncology, Mayo Clinic Phoenix, Phoenix, Arizona

4. Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota

5. Division of Experimental Pathology, Mayo Clinic Rochester, Rochester, Minnesota

6. Division of Hematology, Mayo Clinic Phoenix, Phoenix, Arizona

7. Division of Hematology, Mayo Clinic Jacksonville, Jacksonville, Florida

Abstract

This cohort study examines the role of comprehensive bridging radiotherapy in the setting of chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2818571/jamaoncology_saifi_2024_ld_240006_1720732650.41872.pdf

Reference6 articles.

1. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.;Neelapu;Blood,2023

2. Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?;Saifi;Radiother Oncol,2022

3. Patterns and predictors of failure in recurrent or refractory large B-cell lymphomas after chimeric antigen receptor T-cell therapy.;Figura;Int J Radiat Oncol Biol Phys,2021

4. Don’t put the CART before the horse: the role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma.;Saifi;Int J Radiat Oncol Biol Phys,2023

5. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.;Pinnix;Blood Adv,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy;Blood Advances;2024-09-24

2. Adaptive bridging radiation therapy for relapsed/refractory B-cell lymphoma patient undergoing CAR T-cell therapy: Case report;Clinical and Translational Radiation Oncology;2024-09

3. Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy;Frontiers in Oncology;2024-08-19

4. Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma;HemaSphere;2024-08